COMPANY
Tocagen Inc.
Timeline
- Trial start Phase 1: A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8) source ↗
- Trial start Phase 1: A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care source ↗
- Trial start Phase 1: A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) source ↗
- Trial start Phase 2/Phase 3: The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma source ↗
- Trial start Phase 1: Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor source ↗
- Trial start Phase 1: Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor source ↗
- Trial start Phase 1: A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 source ↗
- Trial start Phase 1: A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma source ↗
Clinical trials (lead sponsor) 8
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT02598011 | A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care | Phase 1 | Withdrawn | 2017-01 | 2022-11 (estimated) |
| NCT04089163 | A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8) | Phase 1 | Withdrawn | 2019-12 | 2022-01 (estimated) |
| NCT04327011 | A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 | Phase 1 | Terminated | 2011-02 | 2019-12 (actual) |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma | Phase 2/Phase 3 | Terminated | Nov 30, 2015 | May 31, 2019 (actual) |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | Phase 1 | Terminated | 2016-07 | 2019-05 (actual) |
| NCT01156584 | A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma | Phase 1 | Completed | 2010-07 | Aug 18, 2016 (actual) |
| NCT01985256 | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | Phase 1 | Completed | 2014-02 | Mar 3, 2016 (actual) |
| NCT01470794 | Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor | Phase 1 | Completed | 2012-02 | Apr 12, 2016 (actual) |
NIH awards 4
- NIH award 5R01FD005732-03 FY2019: $500,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI VISONNEAU, SOPHIE; recipient as written: TOCAGEN, INC., SAN DIEGO, CA. Phase 2/3 Study of Toca 511-Toca FC vs SOC source ↗
- NIH award 5R01FD005732-02 FY2018: $500,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI VISONNEAU, SOPHIE; recipient as written: TOCAGEN, INC., SAN DIEGO, CA. Phase 2/3 Study of Toca 511-Toca FC vs SOC source ↗
- NIH award 1R01FD005732-01 FY2017: $500,000 awarded for that fiscal year; activity R01 (OTHER_NIH); PI DAS, ASHA; recipient as written: TOCAGEN, INC., SAN DIEGO, CA. Phase 2/3 Study of Toca 511-Toca FC vs SOC in Recur source ↗
- NIH award 1R43CA174090-01 FY2012: $269,025 awarded for that fiscal year; activity R43 (SBIR); PI JOLLY, DOUGLAS J.; recipient as written: TOCAGEN, INC., SAN DIEGO, CA. Retroviral replicating vector for prodrug activa source ↗